Isogenic Kidney Glomerulus Chip Engineered from Human Induced Pluripotent Stem Cells
November 4th, 2022
Presented here is a protocol to engineer a personalized organ-on-a-chip system that recapitulates the structure and function of the kidney glomerular filtration barrier by integrating genetically matched epithelial and vascular endothelial cells differentiated from human induced pluripotent stem cells. This bioengineered system can advance kidney precision medicine and related applications.
Overview
This article presents a protocol for engineering a personalized organ-on-a-chip system that mimics the kidney glomerular filtration barrier. By utilizing genetically matched epithelial and vascular endothelial cells derived from human induced pluripotent stem cells, this bioengineered system aims to enhance kidney precision medicine.
Key Study Components
Area of Science
- Bioengineering
- Nephrology
- Stem Cell Research
Background
- Isogenic glomerulus chips enable patient-specific disease modeling.
- Human-induced pluripotent stem cells (IPSCs) can differentiate into various cell types.
- This technology can assess pathological cellular phenotypes.
- It supports the development of personalized medicine applications.
Purpose of Study
- To create a model for nephrotoxicity testing.
- To facilitate drug screening and mechanistic studies.
- To advance kidney precision medicine.
Methods Used
- Engineering of organ-on-a-chip systems.
- Integration of epithelial and endothelial cells from IPSCs.
- Modeling of kidney glomerular filtration barriers.
- Assessment of disease and drug responses.
Main Results
- Successful creation of a patient-specific organ chip.
- Demonstrated potential for modeling kidney diseases.
- Enabled testing of nephrotoxic effects of drugs.
- Provided a platform for personalized medicine applications.
Conclusions
- The organ-on-a-chip system can advance kidney research.
- It offers a novel approach to precision medicine.
- This model can be adapted for broader applications in drug development.
Frequently Asked Questions
Executive Industry Relevance
Patient-specific isogenic kidney glomerulus chips derived from human iPSCs address a critical gap in predictive nephrotoxicity and disease modeling for drug discovery. This platform enables mechanistic de-risking and translational continuity by recapitulating the human glomerular filtration barrier with genetically matched cell types. The approach supports precision medicine initiatives and portfolio triage by enabling functional, patient-relevant assays early in the R&D pipeline.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in a human-relevant, isogenic system.
- Supports biological de-risking by modeling disease phenotypes with patient-matched cells.
- Facilitates functional target validation through lineage-specific marker expression and barrier function.
- Improves predictive confidence for nephrotoxicity and efficacy assessments.
Screening & Assay Development
- Provides a standardized, reproducible platform for compound screening in a physiologically relevant context.
- Delivers quantitative filtration and injury readouts for robust assay development.
- Enables scalability and platform reuse for high-content nephrotoxicity testing.
- Supports reliable evaluation of drug candidates for kidney-specific liabilities.
Translational & Preclinical Research
- Aligns with disease-relevant human biology for translational biomarker discovery.
- Bridges discovery and preclinical validation by modeling patient-specific responses.
- Reduces translational risk by recapitulating human filtration and injury mechanisms.
- Enables risk-adjusted advancement decisions based on functional human data.
Pipeline & Workflow Integration
This isogenic glomerulus chip platform integrates from early discovery through lead identification and preclinical nephrotoxicity assessment, supporting precision medicine workflows.
- Discovery Biology: Facilitates hypothesis testing and mechanistic studies in a patient-specific, human-derived system.
- Screening: Provides assay-ready chips with quantitative, reproducible filtration and injury outputs.
- Analytics: Enables measurement of selective molecular filtration and lineage marker expression for comparative analysis.
- Translational Research: Supports biomarker alignment and continuity from in vitro to preclinical studies.
- Enterprise Reuse: Offers a reusable, scalable platform adaptable to diverse patient backgrounds and disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in kidney research.
- Operational Value: Standardizes nephrotoxicity and disease modeling with reproducible, scalable workflows.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling early, patient-specific risk assessment.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of kidney-targeted therapeutics.
Implementation Considerations
- Requires expertise in iPSC differentiation and microfluidic chip handling.
- Needs access to organ-on-chip bioreactor systems and analytical imaging tools.
- Demands cross-team standardization for cell sourcing, seeding, and readout protocols.
- Adaptation across patient genotypes and disease models may require protocol optimization.
- Potential limitations include technical variability in chip assembly and cell differentiation efficiency.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:59
Preparation of Microfluidic Organ Chip Devices
1:31
Seeding of viECs and Intermediate Mesoderm Cells into the Microfluidic Device
7:15
Podocyte Induction and Chip Maintenance
8:03
Results: Differentiation of viECs and Podocytes on Organ-On-A-Chip Device
9:35
Conclusion
